<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The purpose of this study was to determine whether treatment with high-dose human serum albumin (HSA) would offer protection in a model of high-grade transient forebrain <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>Twenty-six fasted Wistar rats underwent bilateral common carotid <z:mp ids='MP_0006134'>artery occlusion</z:mp> and severe <z:hpo ids='HP_0002615'>hypotension</z:hpo> (50 mmHg) for 10 min </plain></SENT>
<SENT sid="2" pm="."><plain>The agent (25% HSA) or vehicle (0.9% <z:chebi fb="1" ids="26710">NaCl</z:chebi>) was administered i.v </plain></SENT>
<SENT sid="3" pm="."><plain>5 min after termination of <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> </plain></SENT>
<SENT sid="4" pm="."><plain>HSA-treated rats showed significantly improved neurological deficits throughout a 7-day survival period </plain></SENT>
<SENT sid="5" pm="."><plain>Histologically, HSA-treated rats showed 2.4- to 5.3-fold increases in numbers of surviving CA1 hippocampal pyramidal neurons compared to saline-treated animals </plain></SENT>
<SENT sid="6" pm="."><plain>These results document that high-dose albumin therapy instituted 5 min after global <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> significantly improves neurological score and reduces histological damage </plain></SENT>
</text></document>